Literature DB >> 18835574

Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structures.

Anne Jäkel1, Joyce S Plested, J Claire Hoe, Katherine Makepeace, Margaret-Anne J Gidney, Suzanne Lacelle, Frank St Michael, Andrew D Cox, James C Richards, E Richard Moxon.   

Abstract

Sera from healthy infants (under 1 year old), toddlers (3-4 years) and adults (18-65 years) were assayed for their ability to bind to inner core (ic) lipopolysaccharide (LPS) epitopes of Neisseria meningitidis. Antibodies (Abs) reacting to inner core structures, including different substitutions of the first heptose (HepI) and second heptose (HepII) residues of the LPS backbone, truncated and fully extended LPS glycoforms, were detected and for each structure, these inner core antibodies showed an age-related pattern of acquisition. A novel column-based methodology was used to affinity purify IgG antibodies in which purified inner core LPS (derived from a mutant MC58) was covalently linked to Sepharose 4B. Comparison of reactivity before and after affinity purification of the pooled sera showed that the purified Abs bound to the surface of N. meningitidis organisms displaying truncated and extended LPS with a homologous inner core region, promoted the deposition of C3b, were opsonophagocytic in vitro and decreased bacteraemia when used to passively protect infants rats. In addition, the purified Abs were bactericidal in vitro against the mutant strain displaying truncated LPS with a homologous inner core region. These results demonstrate that naturally occurring serum human antibodies to N. meningitidis LPS can access inner core epitopes of encapsulated organisms with a fully extended LPS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835574     DOI: 10.1016/j.vaccine.2008.09.041

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  The oligosaccharide of gonococcal lipooligosaccharide contains several epitopes that are recognized by human antibodies.

Authors:  Ryohei Yamasaki; Uichirou Yabe; Chikako Kataoka; Ushio Takeda; Shunpei Asuka
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

3.  Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: chemical strategies to prepare glycoconjugates with good carbohydrate loading.

Authors:  Andrew D Cox; Frank St Michael; Dhamodharan Neelamegan; Suzanne Lacelle; Chantelle Cairns; James C Richards
Journal:  Glycoconj J       Date:  2010-03-26       Impact factor: 2.916

4.  Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.

Authors:  Noëlle Mistretta; Bruno Guy; Yves Bérard; François Dalençon; Olivia Fratantonio; Christophe Grégoire; Aurélie Lechevallier; Philippe Lhéritier; Laurent Revet; Monique Moreau; Jean Haensler; Bachra Rokbi
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

5.  Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: conjugates based on core oligosaccharides.

Authors:  F St Michael; C M Cairns; A L Filion; A Biolchi; B Brunelli; M Giuliani; J C Richards; A D Cox
Journal:  Glycoconj J       Date:  2013-09-07       Impact factor: 2.916

6.  Antibacterials: A sweet vaccine.

Authors:  David Bundle
Journal:  Nat Chem       Date:  2016-03       Impact factor: 24.427

7.  Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.

Authors:  Jerry C Nagaputra; Christine S Rollier; Manish Sadarangani; J Claire Hoe; Ojas Hrakesh Mehta; Gunnstein Norheim; Muhammad Saleem; Hannah Chan; Jeremy P Derrick; Ian Feavers; Andrew J Pollard; E Richard Moxon
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

8.  Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.

Authors:  Deborah H Schmiel; Elizabeth E Moran; Paul B Keiser; Brenda L Brandt; Wendell D Zollinger
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

9.  An antibacterial vaccination strategy based on a glycoconjugate containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2.

Authors:  Lingbing Kong; Balakumar Vijayakrishnan; Michael Kowarik; Jin Park; Alexandra N Zakharova; Larissa Neiwert; Amirreza Faridmoayer; Benjamin G Davis
Journal:  Nat Chem       Date:  2016-02-01       Impact factor: 24.427

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.